Pechenochnaya entsefalopatiya i printsipy ee lecheniya

Hepatic encephalopathy (HE) is a consequence of liver cell failure; this pathology develops against the background of liver cirrhosis (LC) in almost all known liver diseases (viral and toxic hepatitis, autoimmune liver disease, Wilson's disease, etc.) and is associated with a decrease in volume of functioning liver parenchyma and inability of hepatocytes to maintain homeostasis and implement detoxifying function. Apart etiotropic treatment aimed to elimination the cause of the underlying disease, early detection and correction of HE have a great significance in the management of patients with LC of any cause, because this pathology directly affect the quality of life of patients. The use of L-ornithine-L-aspartate and lactulose not only significantly improves the course and prognosis of HE, but also effectively prevents its development. This determines advisability of administration of L-ornithine-L-aspartate and lactulose for cirrhotic patients even before the first signs of HE.

liver cirrhosis, hepatic encephalopathy, L-ornithine-L-aspartate, lactulose